Compare · AMGN vs SRRK
AMGN vs SRRK
Side-by-side comparison of Amgen Inc. (AMGN) and Scholar Rock Holding Corporation (SRRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and SRRK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $186.59B, about 35.6x SRRK ($5.25B).
- Over the past year, AMGN is up 19.1% and SRRK is up 28.4% - SRRK leads by 9.2 points.
- AMGN has been more active in the news (19 items in the past 4 weeks vs 10 for SRRK).
- AMGN has more recent analyst coverage (25 ratings vs 19 for SRRK).
- Company
- Amgen Inc.
- Scholar Rock Holding Corporation
- Price
- $345.61-1.12%
- $43.79-1.13%
- Market cap
- $186.59B
- $5.25B
- 1M return
- +5.03%
- -5.77%
- 1Y return
- +19.15%
- +28.38%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2018
- News (4w)
- 19
- 10
- Recent ratings
- 25
- 19
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest SRRK
- Director Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)
- Director Reed Joshua was granted 6,839 shares, increasing direct ownership by 43% to 22,571 units (SEC Form 4)
- Director Brudnick Richard was granted 6,839 shares, increasing direct ownership by 45% to 21,896 units (SEC Form 4)
- Director Burow Kristina was granted 6,839 shares, increasing direct ownership by 6% to 117,710 units (SEC Form 4)
- Director Gilman Michael was granted 6,839 shares, increasing direct ownership by 12% to 62,055 units (SEC Form 4)
- Director Peng Katie was granted 6,839 shares, increasing direct ownership by 21% to 39,747 units (SEC Form 4)
- Director Akkaraju Srinivas was granted 6,839 shares, increasing direct ownership by 32% to 27,971 units (SEC Form 4)
- Scholar Rock Holding Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference